The use of thrombolytics and other cardiovascular agents in acute myocardial infarction;BRUK AV TROMBOLYTIKA OG ANDRE MEDIKAMENTER VED AKUTT HJERTEINFARKT

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 14, 1996, Pages 1671-1674

  Reikvam, Åsmund ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NITRIC ACID DERIVATIVE; STREPTOKINASE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; DRUG CONTRAINDICATION; DRUG USE; ELECTROCARDIOGRAM; HUMAN; MAJOR CLINICAL STUDY;

AGED; CARDIOVASCULAR AGENTS; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORWAY;

EID: 0029954007     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Reikvam Å for European Secondary Prevention Study Group. Pasientkarakteristika og mortalitet ved akurt hjerteinfarkt. Tidsskr Nor Lægeforen 1996; 116: 1668-70.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in myocardial infarction. Lancet 1986; 1: 397-402.
3. AIMS Trial Study Group. Effect of intravenous Apsac on mortality- after acute myocardial infarction: preliminary report of a placebocontrolled clinical trial. Lancet 1988; 1: 545-9.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase. oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
5. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525-30.
6. Fibrinolytic Trialists' Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 100 000 patients. Lancet 1994; 343: 311-22.
7. Birkhead J. Time delays in provision of thrombolytic treatment in six district hospitals. BMJ 1992; 305: 445-8.
8. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990; 82: 1510-3.
9. Burrell CJ, Skehan JD, Cowley ML, Barrett CW, Mills PG. Districts' use of thrombolytic agents. BMJ 1990; 300: 237-8.
10. Pashos CL, Normand SL, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. JACC 1994; 23: 1023-30.
11. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-4.
12. Lamas G, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E, for the SAVE investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992, 327: 241-7.
13. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
14. Adams J, Trent R, Rawles J. Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. BMJ 1993; 307: 409-13.
15. Rawles J. Deciding who should have thrombolysis. BMJ 1993; 308: 59-60.
16. Norris RM, Roy S, Dixon GF. What proportion of patients with acute myocardial infarction should receive thrombolytic therapy? Br Heart J 1994; 71: 40.
17. Reikvam Å. Fra kliniske studier til rutinebe-handling. Hva avgjør om forskningsresultater implementeres i klinisk rutine? Tidsskr Nor Lægeforen 1994; 114: 459-61.